Participant‐reported improvement in sialorrhea in the short term · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
1 finding from 1 review
no estimate extracted
1 participants
Moderate
Improvement in neurophysiological parameters at ≤ 3 months · carpal tunnel syndrome
1 finding from 1 review
Muscle strength: maximum voluntary isometric knee extension strength · people with facioscapulohumeral muscular dystrophy
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Time‐scored functional assessments of muscle performance: distance walked · children and adolescents with juvenile dermatomyositis
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Muscle strength · people with facioscapulohumeral muscular dystrophy
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Size of metabolically abnormal areas of myocardium · boys (aged 8 to 16 years old) with subclinical cardiomyopathy in DMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Size of metabolically abnormal areas of myocardium · boys with DMD and left ventricular ejection fraction 45% or more
1 finding from 1 review
Size of metabolically abnormal areas of myocardium · boys with DMD, normal cardiac examination and LVEF > 55% at baseline
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Size of metabolically abnormal areas of myocardium · people with DMD or BMD (ages not stated)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Size of metabolically abnormal areas of myocardium · patients with established cardiomyopathy in DMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cosmetically disabling persistent sequelae ≥ 6 months after randomisation Clinical assessment · Bell's palsy
Corticosteroids showed no clear difference in cosmetically disabling persistent sequelae ≥ 6 months after… compared with placebo or no treatment (low certainty).
1 finding from 1 review
Improvement in 10‐metre walk time at 8 to 12 months1 · patients with IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies
1 finding from 1 review
Change in 10‐metre walking time · patients with Duchenne muscular dystrophy
1 finding from 1 review
Change in 10‐metre walking time · patients with Duchenne muscular dystrophy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Nine‐metre walking/running time: prednisone ‐ daily dose regimen (0.75 mg/kg/day) · patients with Duchenne muscular dystrophy
1 finding from 1 review
Change in timed walk at 6 months (%) e.g. 10‐metre or 6‐minute walk test at 6 months ‐ not measured · people with inclusion body myositis
The review found no eligible studies for this question.
1 finding from 1 review
Change in timed walk at 6 months (%) e.g. 10‐metre or 6‐minute walk test at 6 months ‐ not measured · people with inclusion body myositis
The review found no eligible studies for this question.
1 finding from 1 review
Change in timed walk at 6 months (%) e.g. 10‐metre or 6‐minute walk test at 6 months ‐ not measured · people with inclusion body myositis
The review found no eligible studies for this question.
1 finding from 1 review
Improved muscle function various methods1 · people with myasthenia gravis
1 finding from 1 review
no estimate extracted
10 participants
Very low
Change in 10‐metre walking time · people with fatigue in peripheral neuropathy
1 finding from 1 review